相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Building the design, translation and development principles of polymeric nanomedicines using the case of clinically advanced poly(lactide(glycolide))-poly(ethylene glycol) nanotechnology as a model: An industrial viewpoint
Harivardhan Reddy Lakkireddy et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Key cost drivers of pharmaceutical clinical trials in the United States
Aylin Sertkaya et al.
CLINICAL TRIALS (2016)
Delivery of siRNA targeting tumor metabolism using non-covalent PEGylated chitosan nanoparticles: Identification of an optimal combination of ligand structure, linker and grafting method
Cyril Corbet et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Emerging Frontiers in Drug Delivery
Mark W. Tibbitt et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2016)
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Daniel Bobo et al.
PHARMACEUTICAL RESEARCH (2016)
Critical questions in development of targeted nanoparticle therapeutics
Richard Korsmeyer
REGENERATIVE BIOMATERIALS (2016)
Regulatory aspects on nanomedicines
Vanessa Sainz et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
The similarity question for biologicals and non-biological complex drugs
Daan J. A. Crommelin et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Intracellular siRNA delivery dynamics of integrin-targeted, PEGylated chitosan-poly(ethylene imine) hybrid nanoparticles: A mechanistic insight
Heloise Ragelle et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars
Stefan Muehlebach et al.
NANOMEDICINE (2015)
Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown
Anders Wittrup et al.
NATURE BIOTECHNOLOGY (2015)
Progress in material design for biomedical applications
Mark W. Tibbitt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
How to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider
Huub Schellekens et al.
AAPS JOURNAL (2014)
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
Nicolas Bertrand et al.
ADVANCED DRUG DELIVERY REVIEWS (2014)
Nanomedicines: addressing the scientific and regulatory gap
Sally Tinkle et al.
ANNALS REPORTS (2014)
The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy
L. Sancey et al.
BRITISH JOURNAL OF RADIOLOGY (2014)
EPR: Evidence and fallacy
Joseph W. Nichols et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Challenges facing sterilization and depyrogenation of nanoparticles: Effects on structural stability and biomedical applications'
Melissa A. Vetten et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2014)
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
David Cook et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Non-viral vectors for gene-based therapy
Hao Yin et al.
NATURE REVIEWS GENETICS (2014)
Cancer nanomedicines: So many papers and so few drugs!
Vincent J. Venditto et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines
Marina A. Dobrovolskaia et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines
Falk Ehmann et al.
NANOMEDICINE (2013)
The big picture on nanomedicine: the state of investigational and approved nanomedicine products
Michael L. Etheridge et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2013)
Delivery materials for siRNA therapeutics
Rosemary Kanasty et al.
NATURE MATERIALS (2013)
Phase II and Phase III attrition rates 2011-2012
John Arrowsmith et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Challenges in Development of Nanoparticle-Based Therapeutics
Neil Desai
AAPS JOURNAL (2012)
αVβ3 Integrin-Targeted PLGA-PEG Nanoparticles for Enhanced Anti-tumor Efficacy of a Pt(IV) Prodrug
Nora Graf et al.
ACS NANO (2012)
Scientific considerations for complex drugs in light of established and emerging regulatory guidance
Chris Holloway et al.
ANNALS MEETING REPORTS 2013 (2012)
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Nazila Kamaly et al.
CHEMICAL SOCIETY REVIEWS (2012)
Nanoscale radiotherapy with hafnium oxide nanoparticles
Laurence Maggiorella et al.
FUTURE ONCOLOGY (2012)
Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy
Daniel Zucker et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Doxil® - The first FDA-approved nano-drug: Lessons learned
Yechezkel (Chezy) Barenholz
JOURNAL OF CONTROLLED RELEASE (2012)
Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study
Christoph Mamot et al.
LANCET ONCOLOGY (2012)
Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile
Jeffrey Hrkach et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and prevention
Janos Szebeni et al.
ADVANCED DRUG DELIVERY REVIEWS (2011)
Nanomedicine in cancer therapy: Innovative trends and prospects
Elvin Blanco et al.
CANCER SCIENCE (2011)
In vitro and in vivo characterizations of PEGylated liposomal doxorubicin
Wenlei Jiang et al.
BIOANALYSIS (2011)
The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee
Lesley Seymour et al.
CLINICAL CANCER RESEARCH (2010)
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery
Fabienne Danhier et al.
JOURNAL OF CONTROLLED RELEASE (2010)
Strategies in the design of nanoparticles for therapeutic applications
Robby A. Petros et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Impact of Nanotechnology on Drug Delivery
Omid C. Farokhzad et al.
ACS NANO (2009)
Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with Paclitaxel
Fabienne Danhier et al.
JOURNAL OF CONTROLLED RELEASE (2009)
Dose Escalation Methods in Phase I Cancer Clinical Trials
Christophe Le Tourneau et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Development of Lipidoid-siRNA Formulations for Systemic Delivery to the Liver
Akin Akinc et al.
MOLECULAR THERAPY (2009)
Quality by design for biopharmaceuticals
Anurag S. Rathore et al.
NATURE BIOTECHNOLOGY (2009)
Methods for the Preparation and Manufacture of Polymeric Nanoparticles
Christine Vauthier et al.
PHARMACEUTICAL RESEARCH (2009)
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel
Erin R. Gardner et al.
CLINICAL CANCER RESEARCH (2008)
Clinical pharmacology of liposomal anthracyclines: Focus on pegylated liposomal doxorubicin
Rebecca Solomon et al.
CLINICAL LYMPHOMA & MYELOMA (2008)
Exploiting lymphatic transport and complement activation in nanoparticle vaccines
Sai T. Reddy et al.
NATURE BIOTECHNOLOGY (2007)
Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy
I. Craig Henderson et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
The emerging nanomedicine landscape
Volker Wagner et al.
NATURE BIOTECHNOLOGY (2006)
Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers
MR Dreher et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity
J Szebeni
TOXICOLOGY (2005)
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol)
A Sparreboom et al.
CLINICAL CANCER RESEARCH (2005)
Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
AN Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
